With a newly marketed product in Japan and 10 years of clinical data, regenerative cell therapies promise new options for patients facing a choice between invasive surgery or blindness.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Ethics declarations
Competing interests
A.M. is a consultant at Haystack Sciences and has no competing interests with the companies mentioned in this article.
Rights and permissions
About this article
Cite this article
Marshall, A. Regenerative cell therapy marches into corneal blindness. Nat Biotechnol 43, 1401–1404 (2025). https://doi.org/10.1038/s41587-025-02808-4
Published:
Issue date:
DOI: https://doi.org/10.1038/s41587-025-02808-4
